+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors

Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors

Gynecologic Oncology 119(2): 270-273

The objective of this study was to evaluate patterns of recurrence and prognostic factors as well as the role of adjuvant chemotherapy in stage II-IV ovarian SBT. We performed a retrospective review of all patients with advanced-stage SBT treated at our institution from 1979 to 2008. Advanced stage was defined as FIGO stage II-IV. Progression-free survival (PFS) was defined as the time of diagnosis to time of recurrence/death or last follow-up. Kaplan-Meier method was used to report the PFS rate. A total of 80 stage II-IV patients were identified, of which 15 (19%) were stage II, 63 (79%) were stage III, and 2 (2.5%) were stage IV. The site of metastasis was pelvis in 15 patients (19%), omentum in 29 patients (36%), isolated lymph nodes in 2 patients (2.5%), lung in 1 patient (1%), axilla in 1 patient (1%), and multiple sites in 32 patients (40%). With a median follow-up of 4.8 years, 17 patients (21%) developed recurrent disease. Only patients with metastasis to the omentum or multiple sites developed recurrent disease. Of the 65 stage III/IV patients, 17 patients (26%) received adjuvant chemotherapy following diagnosis. The 3-year progression-free survival (PFS) was 89.9% (95% CI, 77.3-95.7) for patients who did not receive adjuvant chemotherapy compared with 70.6% (95% CI, 43.1-86.6) for patients who received adjuvant chemotherapy. While advanced-stage ovarian SBT generally has a good prognosis, nearly 21% of patients develop recurrent disease with intermediate follow-up. It is unclear from these data if adjuvant chemotherapy influenced PFS.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054899001

Download citation: RISBibTeXText

PMID: 20719369

DOI: 10.1016/j.ygyno.2010.07.019

Related references

Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Research 61(19): 7264-7267, 2001

Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants. Gynecologic Oncology 132(1): 23-27, 2014

Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors. American Journal of Obstetrics and Gynecology 211(6): 637.E1-6, 2015

A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma. Gynecologic Oncology 144(1): 174-180, 2016

MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous borderline tumors: radiologic-pathologic correlation. Journal of Ovarian Research 11(1): 7, 2018

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. Gynecologic Oncology 124(1): 59-62, 2012

Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genetics and Cytogenetics 167(2): 103-108, 2006

Radical surgical therapy and role of adjuvant chemotherapy in ovarian tumors of borderline malignancy. Ceska Gynekologie 69(6): 488-492, 2005

Histopathological Patterns of Microinvasion in Ovarian Serous Borderline Tumors. Current Health Sciences Journal 44(1): 19-22, 2019

Prognosis in patients with serous and mucinous stage I borderline ovarian tumors. International Journal of Gynecological Cancer 22(5): 770-777, 2012

Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 78(2): 278-286, 1996

Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clinical Cancer Research 5(12): 4053-4058, 2000

Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary. Annals of Oncology 25(1): 166-171, 2014

DNA content and Ki-67 expression do not predict outcome in patients with stage II and III ovarian serous borderline tumors. Gynecologic Oncology 72(3): 507, 1999

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. American Journal of Surgical Pathology 29(2): 218-224, 2005